Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00271505
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab (Avastin) — DRUG
    15 mg/kg intravenously (IV) every 3 weeks
  • Carboplatin — DRUG
    AUC 6 IV every 3 weeks
  • Docetaxel — DRUG
    75 mg/m2 IV every 3 weeks

Study Details

The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.

Key Dates

First listed
Jan 2, 2006
Start date
Dec 5, 2005
Status verified
Apr 2020
Primary completion
Jul 27, 2017
Completion
Jul 27, 2017

Study Design

Enrollment
43 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Avastin + Docetaxel + Carboplatin
    Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.

Primary Outcome Measure

Time to Progression-Free Survival (PFS) [ Time Frame: Baseline up to 12 months or disease progression/death ]

Locations (2)

FacilityCityStateZIPSite coordinators
Lyndon Baines Johnson General HospitalHoustonTexas77030-
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Lyndon Baines Johnson General Hospital· Houston, TXUniversity of Texas MD Anderson Cancer Center· Houston, TX

Related Studies